Radius Health Inc (RDUS) : Cqs Cayman Lp added new position in Radius Health Inc during the most recent quarter end. The investment management firm now holds 200,000 shares of Radius Health Inc which is valued at $10,474,000 , the company said in a statement filed on Aug 9, 2016 with the SEC.Radius Health Inc makes up approximately 2.42% of Cqs Cayman Lp’s portfolio.
Other Hedge Funds, Including , Global X Management Co added RDUS to its portfolio by purchasing 124 company shares during the most recent quarter which is valued at $6,397.Cornerstone Advisors boosted its stake in RDUS in the latest quarter, The investment management firm added 113 additional shares and now holds a total of 370 shares of Radius Health Inc which is valued at $17,216. Radius Health Inc makes up approx 0.02% of Cornerstone Advisors’s portfolio.
Radius Health Inc closed down -0.43 points or -0.77% at $55.31 with 8,90,559 shares getting traded on Wednesday. Post opening the session at $56.92, the shares hit an intraday low of $54.01 and an intraday high of $56.92 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Radius Health Inc reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.94.During the same quarter in the previous year, the company posted $-0.61 EPS.
Many Wall Street Analysts have commented on Radius Health Inc. Maxim Group Downgraded Radius Health Inc on Aug 4, 2016 to ” Sell”, Price Target of the shares are set at $24.H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.